6 Result(s)

Article

The Impact of Biosimilar Use on Total Cost of Care and Provider Financial Performance in the Medicare Oncology Care Model: A Population-Based Simulation Study

Payment for oncology care is increasingly moving from fee-for-service to value-based payment (VBP). VBPs are agreements in which providers are held accountable for total cost of care (TCOC) through risk-sharin...

**gyan Yang, Basit I. Chaudhry, Andrew T. Yue, Joshua A. Roth… in Advances in Therapy (2024)

Article

Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study)

To date, there are limited real-world studies published on the use of infliximab-dyyb, a biosimilar to reference product (RP) infliximab approved for the treatment of moderate to severe inflammatory bowel dise...

Bincy Abraham, Bertus Eksteen, Khan Nedd, Hrishikesh Kale… in Advances in Therapy (2022)

Article

Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians

The adoption of oncology biosimilars has been slow in the USA, which may be attributed in part to stakeholder perceptions and lack of operational guidance that supports favorable access to biosimilars.

**gyan Yang, Kelly Blinzler, Joshua Lankin, Sapna Vijayakumar… in BioDrugs (2022)

Article

Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives

Bevacizumab remains the most widely used and most thoroughly characterized angiogenesis inhibitor for a range of advanced cancers. Bevacizumab-bvzr (Zirabev^®), a biosimilar of bevacizumab, was recently approved b...

**gyan Yang, Rongzhe Liu, Varun Ektare… in Applied Health Economics and Health Policy (2021)

Article

Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis

Evidence supports the clinical benefits of early aggressive biologic treatment in patients with rheumatoid arthritis (RA) who have an inadequate response to conventional synthetic disease-modifying antirheumat...

Dipen Patel, Ahmed Shelbaya, Raymond Cheung, Jyoti Aggarwal… in Advances in Therapy (2019)

Article

Economic modeling in HIV for maraviroc in France in treatment experienced patients. Results from the ARAMIS 2011 model

Nicolas Despiegel, Felicitas Kuehne, Monique Martin, Ahmed Shelbaya in Retrovirology (2012)